New York City-based Newtyn Management increased its stake in Indivior by nearly 1.6 million shares in the third quarter, resulting in a net position change of $62.8 million. The fund now holds 4.2 million Indivior shares valued at $101.3 million, making it the fund’s largest holding. As of Friday, shares of Indivior PLC were priced at $35.12, up a staggering 212% over the past year and well outperforming the S&P 500.

New York City-based Newtyn Management reported a buy of nearly 1.6 million additional Indivior PLC shares, increasing its position by an estimated $62.8 million in the third quarter, according to a November 14 SEC filing. According to a filing with the Securities and Exchange Commission dated November 14, Newtyn Management increased its stake in Indivior PLC by nearly 1.6 million shares in the third quarter. The position value rose to $101.3 million at quarter-end, reflecting both buying activity and price changes.

Top holdings after the filing:
NASDAQ:INDV: $101.3 million (12.4% of AUM)
NASDAQ:QDEL: $79.5 million (9.7% of AUM)
NASDAQ:TBPH: $72.3 million (8.8% of AUM)
NYSE:AD: $67.5 million (8.3% of AUM)
NYSE:CNNE: $62.5 million (7.6% of AUM)

Indivior PLC develops and markets buprenorphine-based therapies for opioid use disorder, including SUBLOCADE, SUBUTEX PRO, SUBOXONE, and SUBUTEX, as well as OPVEE nasal spray for opioid overdose and PERSERIS for schizophrenia. The company generates revenue primarily through the sale of proprietary prescription pharmaceuticals targeting substance use and mental health disorders, leveraging a portfolio of both marketed and pipeline products. Indivior serves healthcare providers, addiction treatment centers, and government agencies in the United States, the United Kingdom, and international markets.

Indivior PLC is a specialty pharmaceutical company focused on addressing opioid dependence and related disorders through innovative therapies and a robust product pipeline. The company leverages its expertise in addiction treatment to maintain a leading position in the healthcare sector. Indivior’s strategic investments in research and partnerships support its competitive edge in addressing unmet needs in substance use and mental health treatment.

Read more at Yahoo Finance: Why One Value Fund Has a $101 Million Bet on Indivior Stock Amid a 212% Surge